Assessing risk factors: prevention of inhibitors in haemophilia

被引：26

作者：

Chambost, H. ^{[1
]}

机构：

[1] Univ Aix Marseille 2, Hop Enfants La Timone, Serv Hematol Pediat, F-13385 Marseille 5, France

来源：

HAEMOPHILIA | 2010年 / 16卷

关键词：

epidemiology; haemophilia; inhibitors; PREVIOUSLY UNTREATED PATIENTS; FACTOR-VIII INHIBITORS; CANAL COHORT; POLYMORPHISMS; RECOMBINANT; EXPOSURE; AGE; MANAGEMENT; PRODUCTS; CHILDREN;

D O I：

10.1111/j.1365-2516.2009.02197.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The formation of antibodies against factor VIII or factor IX that inhibit replacement therapy is currently the most serious treatment-related complication faced by patients with haemophilia. This review highlights non-modifiable and modifiable risk factors that determine the development of these antibodies. The non-modifiable risk factors include patient genotype for haemophilia, immunogenotype, ethnicity and positive family history. Age, intensity of treatment and the type of clotting factor administered are identified as modifiable risk factors. These risk factors are likely to be identified more accurately in forthcoming prospective randomized controlled trials and current patient registries. Through a more complete picture of a patient's overall risk profile, individually tailored treatment schedules might be developed that could minimize the incidence of inhibitor formation and thus maximize therapeutic benefit.

引用

页码：10 / 15

页数：6

共 36 条

[1] Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A [J].

Astermark, J. ;

Wang, X. ;

Oldenburg, J. ;

Berntorp, E. ;

Lefvert, A. -K. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (02) :263-265

[2] Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia [J].

Astermark, J .

HAEMOPHILIA, 2006, 12 :52-60

[3] Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A [J].

Astermark, J ;

Oldenburg, J ;

Pavlova, A ;

Berntorp, E ;

Lefvert, AK .

BLOOD, 2006, 107 (08) :3167-3172

[4] The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development [J].

Astermark, J ;

Berntorp, E ;

White, GC ;

Kroner, BL .

HAEMOPHILIA, 2001, 7 (03) :267-272

[5]

ASTERMARK J, 2009, HAEMOPHILIA, P1

[6] Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A [J].

Astermark, Jan ;

Oldenburg, Johannes ;

Carlson, Joyce ;

Pavlova, Anna ;

Kavakli, Kaan ;

Berntorp, Erik ;

Lefvert, Ann-Kari .

BLOOD, 2006, 108 (12) :3739-3745

[7] Inhibitor treatment in haemophillas A and B: Summary statement for the 2006 International Consensus Conference [J].

Berntorp, E. ;

Shapiro, A. ;

Astermark, J. ;

Blanchette, V. S. ;

Collins, P. W. ;

Dimichele, D. ;

Escuriola, C. ;

Hay, C. R. M. ;

Hoots, W. K. ;

Leissinger, C. A. ;

Negrier, C. ;

Oldenburg, J. ;

Peerlinck, K. ;

Reding, M. T. ;

Hart, C. .

HAEMOPHILIA, 2006, 12 :1-7

[8] Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A [J].

Chalmers, E. A. ;

Brown, S. A. ;

Keeling, D. ;

Liesner, R. ;

Richards, M. ;

Stirling, D. ;

Thomas, A. ;

Vidler, V. ;

Williams, M. D. ;

Young, D. .

HAEMOPHILIA, 2007, 13 (02) :149-155

[9] Relevance of early paediatric care for boys with severe haemophilia [J].

Chambost, H. ;

Meunier, S. .

ARCHIVES DE PEDIATRIE, 2006, 13 (11) :1423-1430

[10] Inhibitors in haemophilia: clinical aspects [J].

DiMichele, D ;

Rivard, G ;

Hay, C ;

Antunes, S .

HAEMOPHILIA, 2004, 10 :140-145

← 1 2 3 4 →